Farampator

From Wikipedia, the free encyclopedia

Jump to: navigation, search
Farampator
Farampator.svg
Farampator ball-and-stick model.png
Systematic (IUPAC) name
2,1,3-benzoxadiazol-6-yl-piperidin-1-ylmethanone
Clinical data
Legal status
  • Investigational New Medicine
Identifiers
CAS Registry Number 211735-76-1 YesY
ATC code None
PubChem CID: 4118151
ChemSpider 3331565 N
UNII 7X6P5N8K2L N
KEGG D04131 YesY
Synonyms Farampator, CX-691
Chemical data
Formula C12H13N3O2
Molecular mass 231.25052 g/mol
 N (what is this?)  (verify)

Farampator (CX-691, Org 24448) is an ampakine drug. It was developed by Cortex Pharmaceuticals, and licensed to Organon BioSciences for commercial development. Following the purchase of Organon by Schering-Plough in 2007, the development license to farampator has been transferred, and development is continuing.

Farampator has been investigated for its effect on AMPA receptors and researched for potential use in the treatment of schizophrenia and Alzheimer's Disease. It was found to improve short-term memory, but impaired episodic memory. It produced side effects (SEs) such as headache, somnolence and nausea. Subjects with SEs had significantly higher plasma levels of farampator than subjects without SEs. Additional analyses revealed that in the farampator condition the group without SEs showed a significantly superior memory performance relative to the group with SEs. [1]

References[edit]

  1. ^ Wezenberg E, Verkes RJ, Ruigt GS, Hulstijn W, Sabbe BG. Acute effects of the ampakine farampator on memory and information processing in healthy elderly volunteers. Neuropsychopharmacology. 2007 Jun;32(6):1272-83. doi:10.1038/sj.npp.1301257 PMID 17119538